Enhanced antibody responses in fully vaccinated individuals against pan-SARS-CoV-2 variants following Omicron breakthrough infection
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jeong, Hye Won | - |
dc.contributor.author | Se-Mi Kim | - |
dc.contributor.author | Min Kyung Jung | - |
dc.contributor.author | Noh, Ji Yun | - |
dc.contributor.author | Ji-Seung Yoo | - |
dc.contributor.author | Kim, Eun-Ha | - |
dc.contributor.author | Young-Il Kim | - |
dc.contributor.author | Yu, Kwangmin | - |
dc.contributor.author | Seung-Gyu Jang | - |
dc.contributor.author | Gil, Juryeon | - |
dc.contributor.author | Mark Anthony Casel | - |
dc.contributor.author | Rollon Rare | - |
dc.contributor.author | Choi, Jeong Ho | - |
dc.contributor.author | Kim, Hee-Sung | - |
dc.contributor.author | Kim, Jun Hyoung | - |
dc.contributor.author | Um, Jihye | - |
dc.contributor.author | Chaeyoon Kim | - |
dc.contributor.author | Kim, Yeonjae | - |
dc.contributor.author | Chin, Bum Sik | - |
dc.contributor.author | Jung, Sungmin | - |
dc.contributor.author | Choi, Jun Yong | - |
dc.contributor.author | Song, Kyoung-Ho | - |
dc.contributor.author | Kim, Yong-Dae | - |
dc.contributor.author | Park, Jun-Sun | - |
dc.contributor.author | Song, Joon Young | - |
dc.contributor.author | Eui-Cheol Shin | - |
dc.contributor.author | Young Ki Choi | - |
dc.date.accessioned | 2023-01-26T02:43:08Z | - |
dc.date.available | 2023-01-26T02:43:08Z | - |
dc.date.created | 2022-10-29 | - |
dc.date.issued | 2022-10 | - |
dc.identifier.issn | 2666-3791 | - |
dc.identifier.uri | https://pr.ibs.re.kr/handle/8788114/12700 | - |
dc.description.abstract | © 2022 The Author(s)Omicron has become the globally dominant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant, creating additional challenges due to its ability to evade neutralization. Here, we report that neutralizing antibodies against Omicron variants are undetected following COVID-19 infection with ancestral or past SARS-CoV-2 variant viruses or after two-dose mRNA vaccination. Compared with two-dose vaccination, a three-dose vaccination course induces broad neutralizing antibody responses with improved durability against different SARS-CoV-2 variants, although neutralizing antibody titers against Omicron remain low. Intriguingly, among individuals with three-dose vaccination, Omicron breakthrough infection substantially augments serum neutralizing activity against a broad spectrum of SARS-CoV-2 variants, including Omicron variants BA.1, BA.2, and BA.5. Additionally, after Omicron breakthrough infection, memory T cells respond to the spike proteins of both ancestral and Omicron SARS-CoV-2 by producing cytokines with polyfunctionality. These results suggest that Omicron breakthrough infection following three-dose mRNA vaccination induces pan-SARS-CoV-2 immunity that may protect against emerging SARS-CoV-2 variants of concern. | - |
dc.language | 영어 | - |
dc.publisher | Cell Press | - |
dc.title | Enhanced antibody responses in fully vaccinated individuals against pan-SARS-CoV-2 variants following Omicron breakthrough infection | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.identifier.wosid | 000917310900002 | - |
dc.identifier.scopusid | 2-s2.0-85139299618 | - |
dc.identifier.rimsid | 79011 | - |
dc.contributor.affiliatedAuthor | Se-Mi Kim | - |
dc.contributor.affiliatedAuthor | Min Kyung Jung | - |
dc.contributor.affiliatedAuthor | Ji-Seung Yoo | - |
dc.contributor.affiliatedAuthor | Young-Il Kim | - |
dc.contributor.affiliatedAuthor | Seung-Gyu Jang | - |
dc.contributor.affiliatedAuthor | Mark Anthony Casel | - |
dc.contributor.affiliatedAuthor | Rollon Rare | - |
dc.contributor.affiliatedAuthor | Chaeyoon Kim | - |
dc.contributor.affiliatedAuthor | Eui-Cheol Shin | - |
dc.contributor.affiliatedAuthor | Young Ki Choi | - |
dc.identifier.doi | 10.1016/j.xcrm.2022.100764 | - |
dc.identifier.bibliographicCitation | Cell Reports Medicine, v.3, no.10 | - |
dc.relation.isPartOf | Cell Reports Medicine | - |
dc.citation.title | Cell Reports Medicine | - |
dc.citation.volume | 3 | - |
dc.citation.number | 10 | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Cell Biology | - |
dc.relation.journalResearchArea | Research & Experimental Medicine | - |
dc.relation.journalWebOfScienceCategory | Cell Biology | - |
dc.relation.journalWebOfScienceCategory | Medicine, Research & Experimental | - |
dc.subject.keywordPlus | NEUTRALIZING ANTIBODIES | - |
dc.subject.keywordPlus | SARS-COV-2 | - |
dc.subject.keywordPlus | IMMUNITY | - |
dc.subject.keywordPlus | MATURATION | - |
dc.subject.keywordPlus | BREADTH | - |
dc.subject.keywordPlus | POTENCY | - |
dc.subject.keywordAuthor | recovered patient | - |
dc.subject.keywordAuthor | SARS-CoV-2 | - |
dc.subject.keywordAuthor | T cell immune response | - |
dc.subject.keywordAuthor | variants of concern | - |
dc.subject.keywordAuthor | ancestral | - |
dc.subject.keywordAuthor | breakthrough infection | - |
dc.subject.keywordAuthor | cross-neutralization | - |
dc.subject.keywordAuthor | D614G | - |
dc.subject.keywordAuthor | mRNA vaccine | - |
dc.subject.keywordAuthor | Omicron BA.1 | - |
dc.subject.keywordAuthor | Omicron BA.2 | - |